Pulmonary Artery DopplerNCT06755073
Pulmonary Artery Doppler in Preeclamptic Mothers
An observational study of Pulmonary Artery Doppler, run by Assiut University at 1 site in Egypt.
Trial summary
Evaluation of Pulmonary artery Doppler parameters in fetuses of mothers with severe preeclampsia Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Pulmonary Artery Doppler
- What is being tested?
- Pulmonary artery Doppler ultrasound
- Type of treatment
- Surgery or procedure
- How many people
- 86 participants
- Where
- 1 siteEgypt
- Study dates
- 31 Dec 2024to 10 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: Pregnant woman with preeclampsia
Who may be able to join
- preeclampsia patients Pregnant 28 -37 weeks
Who cannot join
- fetal death Congenital fetal anomalies Fetal Cardiac arrhythmia
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Fetal Pulmonary Artery Doppler in Mothers With Preeclampsia for Detecting Neonatal Respiratory Distress
Evaluation of Pulmonary artery Doppler parameters in fetuses of mothers with severe preeclampsia
Read the detailed description
Preclampsia (PE) represent a major concern in public health, affecting 2-8% of all pregnancies and considered one of the leading causes of perinatal morbidity and mortality. fetal growth restriction (FGR) ia also a common health problem affecting about 5-10% of all pregnancies and commonly associates with preeclampsia . It is estimated that 20% of cases of PE present with FGR and about 50% of early-onset FGR cases will eventually coexist with PE.
Preeclampsia affects about 5% of pregnancies and hypertensive disorders of pregnancy cause over 60,000 maternal fatalities each year around the world .The decision to deliver a woman with severe pre-eclampsia that is far from the term [mid-trimester] is difficult for the obstetrician.In most cases of highly premature pre-eclamptic gestation, certain institutions propose continuing pregnancy until one of the following occurs development of fetal lung maturity, development of fetal or maternal discomfort, or accomplishment of gestational age of 34 to 36-week of gestation .
Numerous tests have been developed in an attempt to identify if fetal lung maturation has reached a level sufficient to prevent the development of fetal RDS. These tests are based on four core themes: biochemical testing for active surfactant components, biophysical testing for surfactant functionality, physical testing of amniotic fluid opacity, and ultrasound examination of the fetuses and their tissues . Neonatal RDS has been predicted using fetal pulmonary artery Doppler. Kim and colleagues discovered that a high PAT/ET was linked to newborn RDS .The development of RDS in preterm newborns is linked to an increased acceleration time to ejection time [AT/ET] ratio in the fetal pulmonary artery .
- Conditions
- Pulmonary Artery Doppler
- Being tested
- Pulmonary artery Doppler ultrasound
- Keywords
- Pulmonary Doppler, Preeclampsia
- Medical subject headings
- Pre-Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulmonary artery Doppler ultrasoundRadiation
Doppler ultrasound of fetal pulmonary artery
| Study group | Role | What they receive |
|---|---|---|
| Pulmonary artery Doppler | The four chamber view, outflow tract views, triple vessel view, longitudinal view of the aortic arch and ductal arch, and colour flow mapping will be used for a comprehensive examination to assess structural heart integrity and rule out cardiac defects. Pulmonary artery is detected and power Doppler cursor is put on it just beyond pulmonary valve and indices are calculated. Receives: Radiation: Pulmonary artery Doppler ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pulmonary Doppler resistance index
Pulmonary Doppler index in fetus of preeclamptic mother
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jan 2025
- Study start31 Dec 2024
- Primary completion30 Nov 2025
- Study completion10 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Artery DopplerStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 86 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Gamal M.fekry, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06755073
- Sponsor's protocol ID
- PAD
- Status last verified
- Apr 2026
- First submitted
- 12 Dec 2024
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fetal Pulmonary Artery Doppler in Mothers With Preeclampsia for Detecting Neonatal Respiratory Distress
- ClinicalTrials.gov ID
- NCT06755073
- Acronym / sponsor ID
- PAD
- Conditions
- Pulmonary Artery Doppler
- Keywords
- Pulmonary Doppler, Preeclampsia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 86 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 31 Dec 2024 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 10 Dec 2025 (actual)
- First posted
- 1 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of Pulmonary artery Doppler parameters in fetuses of mothers with severe preeclampsia
Detailed description
Preclampsia (PE) represent a major concern in public health, affecting 2-8% of all pregnancies and considered one of the leading causes of perinatal morbidity and mortality. fetal growth restriction (FGR) ia also a common health problem affecting about 5-10% of all pregnancies and commonly associates with preeclampsia . It is estimated that 20% of cases of PE present with FGR and about 50% of early-onset FGR cases will eventually coexist with PE.
Preeclampsia affects about 5% of pregnancies and hypertensive disorders of pregnancy cause over 60,000 maternal fatalities each year around the world .The decision to deliver a woman with severe pre-eclampsia that is far from the term [mid-trimester] is difficult for the obstetrician.In most cases of highly premature pre-eclamptic gestation, certain institutions propose continuing pregnancy until one of the following occurs development of fetal lung maturity, development of fetal or maternal discomfort, or accomplishment of gestational age of 34 to 36-week of gestation .
Numerous tests have been developed in an attempt to identify if fetal lung maturation has reached a level sufficient to prevent the development of fetal RDS. These tests are based on four core themes: biochemical testing for active surfactant components, biophysical testing for surfactant functionality, physical testing of amniotic fluid opacity, and ultrasound examination of the fetuses and their tissues . Neonatal RDS has been predicted using fetal pulmonary artery Doppler. Kim and colleagues discovered that a high PAT/ET was linked to newborn RDS .The development of RDS in preterm newborns is linked to an increased acceleration time to ejection time [AT/ET] ratio in the fetal pulmonary artery .
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pulmonary artery Doppler | – | Radiation: Pulmonary artery Doppler ultrasoundThe four chamber view, outflow tract views, triple vessel view, longitudinal view of the aortic arch and ductal arch, and colour flow mapping will be used for a comprehensive examination to assess structural heart integrity and rule out cardiac defects. Pulmonary artery is detected and power Doppler cursor is put on it just beyond pulmonary valve and indices are calculated. |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Pregnant woman with preeclampsia
Key inclusion criteria (1 listed)
- preeclampsia patients Pregnant 28 -37 weeks
Key exclusion criteria (1 listed)
- fetal death Congenital fetal anomalies Fetal Cardiac arrhythmia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulmonary artery Doppler ultrasoundDoppler ultrasound of fetal pulmonary artery | Radiation | Pulmonary artery Doppler |
Primary outcome
Pulmonary Doppler resistance index
Time frame: 1 month
Pulmonary Doppler index in fetus of preeclamptic mother
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
Related trials for Pulmonary Artery Doppler
Not yet recruitingObservational study
Vascular Health and Function in Cystic Fibrosis
Cystic Fibrosis, Endothelial Dysfunction
Enrolling by invitationObservational study
Multimodal Physiologic State Intelligence Study
Heart Failure, Cardiomyopathies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Artery Doppler, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pulmonary Doppler resistance index (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.